Novartis cannot block generic of best-selling heart drug, US appeals court says
Portfolio Pulse from
Novartis has been unsuccessful in its attempt to prevent MSN Pharmaceuticals from launching a generic version of its heart drug Entresto, as ruled by a U.S. appeals court.
December 04, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novartis' attempt to block a generic version of its heart drug Entresto by MSN Pharmaceuticals has been denied by a U.S. appeals court. This could lead to increased competition and potential revenue loss for Novartis.
The court's decision allows MSN Pharmaceuticals to produce a generic version of Entresto, which is a best-selling drug for Novartis. This could lead to a decrease in market share and revenues for Novartis as generics typically sell at lower prices, attracting cost-sensitive customers.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90